Charles River Laboratories
336 hedge funds and large institutions have $4.96B invested in Charles River Laboratories in 2017 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 130 increasing their positions, 109 reducing their positions, and 20 closing their positions.
180% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 20
19% more repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 109
11% more funds holding
Funds holding: 302 → 336 (+34)
7% more capital invested
Capital invested by funds: $4.65B → $4.96B (+$312M)
0.01% less ownership
Funds ownership: 96.51% → 96.5% (-0.01%)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
63% less call options, than puts
Call options by funds: $1.57M | Put options by funds: $4.24M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
+$77.7M |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$42.9M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$41.7M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$33.5M |
| 5 |
Goldman Sachs
New York
|
+$28.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$103M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$58.2M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
-$39.4M |
| 4 |
AI
Ariel Investments
Chicago,
Illinois
|
-$27.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$26.1M |
CRL Hedge Fund Activity: Q3 2017 in Review
336 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q3 2017, worth a combined $4.96B — up 6.7% from $4.65B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new CRL positions and 20 closed out — a net gain of 36 holders — while 130 added to existing stakes and 109 trimmed.
The largest buyer was Congress Asset Management, opening a new position worth an estimated $77.7M. The largest seller was Millennium Management, cutting an estimated $103M.
- 336 institutional investors held Charles River Laboratories (CRL) as of Q3 2017, up from 302 in Q2 2017.
- Funds reported $4.96B of Charles River Laboratories stock for Q3 2017, up 6.7% quarter-over-quarter.
- 56 funds opened new Charles River Laboratories positions in Q3 2017 and 20 closed out, a net change of +36 holders.
- The largest Charles River Laboratories buyer in Q3 2017 was Congress Asset Management, an estimated $77.7M added.
- The largest Charles River Laboratories seller in Q3 2017 was Millennium Management, an estimated $103M sold.
Based on aggregated 13F filings for Q3 2017.